Single source: Childhood Cancer Survivor Study (U24 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for research institutions and cancer centers studying childhood cancer survivors. Eligible applicants include public and private research institutions, universities, and cancer research organizations. The grant supports data collection, analysis, and management activities related to long-term outcomes in childhood cancer survivors. Clinical trial development is explicitly not allowed under this mechanism.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Mar 18, 2026 Applications open
- Sep 25, 2026 Application deadline in 71 days
- Jul 1, 2027 Award announced
- Jul 1, 2027 Project start
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support the continuation of the Childhood Cancer Survivor Study (CCSS) that investigates the long-term morbidity and mortality associated with cancer treatments. The CCSS represents a multi-institutional, multidisciplinary collaborative research resource that currently has health-related data from 38,000 or more 5-year survivors of pediatric and adolescent cancer patients with a comparison sibling control cohort. This NOFO seeks to obtain additional age-related longitudinal information from the current cohort of survivors and to include pediatric cancer survivors receiving modern therapies. The goal of the CCSS is to serve as a data resource and a biorepository for researchers. The objectives are to use the resources to conduct cancer risk assessments, observational and intervention-based research studies associated with long-term outcomes across the life span of survivors with the intent of improving cancer treatments. This is a Forecast for a single source that will invite application(s) from eligible organization(s) to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Who can apply
Eligible applicants
Demographic focus
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (R&R) Application for Federal Assistance
- Project Narrative (specific aims, research design, methods)
- Budget and Budget Justification
- Biographical sketches of key personnel (NIH format)
- Research Strategy
- Data Management and Sharing Plan
- Institutional support and commitment letters
Program contact
- 👤 NCI CCSS RFA
- 📧 NCICCSSRFA@mail.nih.gov
- 📞 Please contact via e-mail
Funding track record
Recent awards under CFDA 93.395 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$353,109,533
-
$226,323,195
-
$180,463,644
-
$148,820,579
-
$143,093,026
-
$125,672,442
-
$124,513,663
-
$112,462,142
-
$109,067,856
-
$104,790,648
Top States by Funding
- CA 10 awards $871.7M
- PA 5 awards $513.3M
- NY 7 awards $462.6M
- MA 7 awards $282.7M
- IL 3 awards $274.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.395). How funding has trended year over year.
| 2024 | $1,298,551,504 | |
| 2025 | $1,414,965,434 | |
| 2026 est. | $926,626,977 |
FAQ
Who can apply for this grant?
Research institutions, universities, and cancer centers with expertise in childhood cancer survivorship research. Applicants must have institutional capacity to manage large datasets and participant populations.
What type of research is supported?
Data collection, longitudinal follow-up studies, outcome analysis, and survivorship research. Clinical trial development is not permitted under this funding mechanism.
What are the key deadlines?
The application opens in March 2026. Check NIH's grants.gov portal for specific submission deadlines and no-cost extension policies.
How competitive is this funding?
NIH grants are highly competitive. You'll need strong preliminary data, a seasoned research team, and clear scientific significance to be competitive.
What is the typical funding level?
U24 mechanism awards vary. Review recent NIH notices for this CFDA code to see typical project periods and budgets.
💡 Tips for applicants
- Demonstrate significant preliminary data on childhood cancer survivors and a clear research or data management plan.
- Build a multidisciplinary team with oncology, survivorship, epidemiology, and biostatistics expertise.
- Address long-term health outcomes, late effects, or quality of life endpoints that matter to the scientific community.
- Use NIH's RISP system and work with your grants office early to meet institutional review and compliance requirements.
- Show how your data or study will advance the field beyond the current Childhood Cancer Survivor Study cohort.
⚠️ Common mistakes
Submitting clinical trial protocols when the mechanism explicitly prohibits them. Not demonstrating adequate preliminary data or institutional capacity to manage a large, complex dataset. Failing to align with NIH's cancer research priorities or the specific goals of childhood cancer survivorship science.
Similar grants
- OPEN Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) — National Institutes of Health
- CLOSED Forecast to Publish a Funding Opportunity Announcement for Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) — National Institutes of Health
- OPEN Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) — National Institutes of Health